Jiangsu Hengrui rises on licensing deal with Novo Nordisk for obesity drug
29/09/2026 06:33
BUZZ-Jiangsu Hengrui rises on licensing deal with Novo Nordisk for obesity drug ** Hong Kong shares of Jiangsu Hengrui Pharmaceuticals 1276.HK rise 6.1% to HK$47.5
** Shanghai-listed stock 600276.SS climbs 3.7% to 46.13 yuan
** China's largest drugmaker by market value said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S NOVOb.CO in a deal worth up to $2.6 billion
** Novo Nordisk gains exclusive rights to develop, manufacture and commercialise the drug outside certain regions, with the Danish drugmaker paying an upfront fee of $300 million
** YTD, Hong Kong stock down 34.6%, Shanghai shares down 23%, while Hang Seng Biotech Index .HSBIO up 13.1%
(Reporting by Donny Kwok)
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals